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DISCUSSION
Dr Anil Hingorani (Brooklyn, NY). While there has been a
tremendous amount of data on CRP in the cardiology literature
for the last 20 years, it really hasn’t had much clinical impact.
How is this data going to change what you do every day to your
patients undergoing lower extremity bypass procedures?
Dr Christopher D. Owens. I think that right now, we
would be hesitant to make any recommendations based on 91
patients other than pointing out that our median hsCRP level
was 3.2 mg/L, which is high risk. Five mg/L, which was our
lab’s cutoff, may be a little bit too high. Once we get more
patients, we may be able to place these in tertiles or quartiles and
refine the predictive ability. Depending on the difference be-
tween the highest and lowest quartile, there may be an oppor-
tunity for treatment. As you know, there is beneficial data on
statins lowering CRP and improving cardiovascular outcomes.
And if that is true, CRP is a biomodulator, not just a bio-
marker, and that may have direct clinical impact in terms of
decreasing progressive atherosclerosis or decreasing vein graft
hyperplasia. So it may be an area for pharmaceutical inter-
vention.
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As described in the article, many millions of individuals world-
wide suffer from peripheral artery disease. In the United States alone,
up to 100,000 peripheral artery reconstructions are performed each
year. Because atherosclerosis is an inflammatory disease, it is logical to
be interested in determining the role of different inflammatory mark-
ers for prognostic and potential therapy-guiding purposes.
In this particular study, the authors found that patients pre-
senting with chronic limb ischemia (CLI) had an increase in
high-sensitivity C-reactive protein (CRP), fibrinogen, and serum
amyloid levels. The most striking finding was that patients with the
highest levels of high-sensitivity CRP (0.5 mg/L) before surgery
experienced a 60% incidence ofmajor postoperative vascular events. It
is difficult to assign importance, however, because the CLI group was
not compared with an age-matched control group without CLI.
Although the study has some design flaws, it should be of
interest to all who treat or monitor patients with CLI. The study
was also limited because it only measured the inflammatory
markers before open leg bypass.
I believe that identifying markers that predict success or
failure for treating CLI patients is even more important in
evaluating the evolving endovascular treatment techniques for
CLI. One hopes that identifying a specific marker, or a panel of
relevant markers, will contribute to predicting the success of
open and endovascular procedures for CLI as well as provide
some idea of long-term risk for major atherosclerotic vascular
events in these complex patients. This important study presents
the reader with insight into the future for monitoring and
treating CLI patients.
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